Stock Groups

Pfizer recalls all lots of anti-smoking drug over carcinogen presence By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO. A man walks by a Pfizer logo during the COVID-19 pandemic, which occurred in Manhattan, New York City. It took place on April 1, 2021. REUTERS/Carlo Allegri

(Reuters) – Pfizer Inc (NYSE:) said on Thursday it was recalling all lots of its anti-smoking treatment, Chantix, due to high levels of cancer-causing agents called nitrosamines in the pills.

Pfizer Inc (NYSE:) halted the distribution of Chantix in June and has already recalled several lots.

Pfizer requested distributors and wholesalers to immediately stop selling the tablet.

The company said there was no immediate risk to patients

taking Chantix, but advised them to consult with their health care provider to check the availability of alternative treatments.

Chantix was approved as a prescription drug by the FDA on May 6, 2006. The medication is used to aid adults over 18 who want to quit smoking. It can be taken for 12-24 weeks.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]